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Effects of an Unusual Poison Identify a Lifespan Role for Topoisomerase 2 in 
Saccharomyces Cerevisiae 
Abstract 
A progressive loss of genome maintenance has been implicated as both a cause and consequence of 
aging. Here we present evidence supporting the hypothesis that an age-associated decay in genome 
maintenance promotes aging in Saccharomyces cerevisiae (yeast) due to an inability to sense or repair 
DNA damage by topoisomerase 2 (yTop2). We describe the characterization of LS1, identified in a high 
throughput screen for small molecules that shorten the replicative lifespan of yeast. LS1 accelerates 
aging without affecting proliferative growth or viability. Genetic and biochemical criteria reveal LS1 to be a 
weak Top2 poison. Top2 poisons induce the accumulation of covalent Top2-linked DNA double strand 
breaks that, if left unrepaired, lead to genome instability and death. LS1 is toxic to cells deficient in 
homologous recombination, suggesting that the damage it induces is normally mitigated by genome 
maintenance systems. The essential roles of yTop2 in proliferating cells may come with a fitness trade-
off in older cells that are less able to sense or repair yTop2-mediated DNA damage. Consistent with this 
idea, cells live longer when yTop2 expression levels are reduced. These results identify intrinsic 
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The longevity of an organism is determined by a 
confounding combination of genes and environment.  
Lifespan assays in model organisms have identified 
numerous longevity genes—those that when mutated or 
when over- or underexpressed affect mean and/or 
maximum lifespan—with primary roles in many cell 
processes, including genome maintenance, metabolism, 
mitochondrial function, and oxidative stress [1, 2]. The 
lifespan of Saccharomyces cerevisiae (yeast) is 
measured using chronological or replicative models, 
both of which respond similarly to environmental 
interventions such as caloric restriction and oxidative 
stress [3].  While there is no correlation between the 
chronological and replicative lifespans of natural yeast 
isolates [4], the two methods have  yielded  overlapping  
 
 
sets of longevity genes, and both have identified 
longevity pathways or genes with relevance to 
mammalian aging. The standard method for quantifying 
replicative lifespan (RLS) is slow and tedious because it 
requires the manual microdissection of daughter cells 
from their mothers, but see [5, 6]. In this study we 
describe improvements to the high throughput capable 
Death of Daughters (DeaD) RLS proxy assay [7], and 
employ it in a screen for small molecules that shorten 
RLS without affecting proliferation or viability.  
 
Here we characterize LS1, a RLS shortening molecule 
that acts by poisoning yeast topoisomerase 2 (yTop2). 
yTop2 is an essential enzyme that generates transient 
double strand breaks (DSBs) in order to relieve positive 
and negative DNA supercoils during replication, 
transcription and DNA repair, and to separate tangled 
























that  shorten  the  replicative  lifespan of yeast. LS1 accelerates aging without affecting proliferative growth or
viability.     Genetic  and  biochemical  criteria  reveal  LS1  to  be  a weak  Top2  poison.  Top2  poisons  induce  the
accumulation  of  covalent  Top2‐linked  DNA  double  strand  breaks  that,  if  left  unrepaired,  lead  to  genome
instability and death. LS1 is toxic to cells deficient in homologous recombination, suggesting that the damage it
induces  is normally mitigated by genome maintenance  systems. The essential  roles of yTop2  in proliferating
cells may come with a fitness trade‐off in older cells that are less able to sense or repair yTop2‐mediated DNA
damage. Consistent with  this  idea, cells  live  longer when yTop2 expression  levels are  reduced. These  results
identify intrinsic yTop2‐mediated DNA damage as a potentially manageable cause of aging.  
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(concatenated) chromosomes prior to mitosis [8].  Top2 
poisons stabilize Top2-DNA covalent complexes 
(Top2ccs) in which the 5’-phosphate ends of the double 
strand break are linked to the enzyme via 
phosphotyrosine ester bonds. If left unrepaired Top2ccs 
disrupt transcription and replication and lead to genome 
instability, senescence and cell death [9, 10].  Top2 
poisons include widely used chemotherapeutic drugs, 
but are also found in foods and in the environment [11].  
DNA abasic sites, alkylated bases, and UV-induced 
lesions are also capable of stabilizing Top2-DNA 
adducts [11]. This is relevant to the potential role of 
Top2 in aging because all of these base modifications 
and lesions accumulate in aging cells and tissues [12]. 
Genetic programs that recognize and repair Top2ccs, 
including specific tyrosyl phosphodiesterases and 
nucleases [13-15] and DNA repair systems [16, 17], 
support the notion that Top2ccs are a normal fact of life. 
Chemotherapeutic Top2 poisons kill dividing (cancer) 
cells by overloading these remediation mechanisms 
with large numbers of Top2ccs. 
 
The simplest explanation for our results is that LS1 is 
selectively toxic to aging cells that have a diminished 
capacity to repair Top2ccs. In support of this hypothesis 
we show that reducing TOP2 expression is sufficient to 
extend RLS.  Previous evidence in support of the DNA 
damage theory of aging is based on observations and 
experiments that link DNA damage to reductions in 
longevity.  Our results show that native levels of DNA 




Death of Daughters (DeaD) assay recapitulates 
aspects of replicative aging 
 
The DeaD assay is a high throughput proxy for the 
standard RLS microdissection assay, which is slow and 
labor intensive [7]. The DeaD assay is based on the 
W303R derived strain K6001 that was engineered to 
study mother cell specific mating type switching [18, 
19]. As described in the Supplementary Data we 
reconstructed and greatly improved the performance of 
the original DeaD strain (Supplemental Figs. S1, S2 & 
S3).  DeaD strains contain two chromosomal copies of 
the essential CDC6 gene, one under the control of the 
inducible GAL1 promoter and the other under the 
control of the mother-specific HO promoter. In 
galactose-containing medium, both mothers and 
daughters express CDC6, predominately from the GAL1 
promoter, and divide exponentially. In glucose-
containing medium, daughter division is strongly 
inhibited due to the lack of expression of CDC6 from 
either promoter, and the growth rate and saturation 
point of the culture becomes limited by the reproductive 
capacity of the mother cells rather than nutrient 
limitation.  
 
The DeaD assay recapitulates lifespan shortening and 
extension associated with under- and over-expression of 
SIR2 (Fig. S3). The DeaD assay also recapitulates 
lifespan shortening by a number of gene deletions 
previously shown by microdissection assay to shorten 
RLS, including sir2Δ, sgs1Δ, rad9Δ, rad51Δ, rad52Δ, 
phb1Δ, and isw1Δ (Fig. S4), but does not show RLS 
extension in many strains containing gene deletions 
known to extend RLS (including tor1Δ and hxk2Δ). 
Therefore, in this report we focused on the 
demonstrated utility of the DeaD assay to report RLS 
shortening.  
 
High throughput screen for small molecules that 
shorten replicative lifespan 
 
Small molecules that reduce DeaD cell growth under 
restrictive conditions, but minimally affect growth 
under permissive condition, are candidate probes that 
target longevity factors. An essential criterion for 
meaningful RLS shortening is a lack of toxicity at doses 
where statistically significant RLS shortening is 
observed.  It is not interesting to shorten “apparent” 
RLS simply by making cells sick.  
 
The DeaD assay was used to screen a 138,758 
compound NIH small molecule library for those that 
reduced growth in glucose (restrictive) without 
significantly affecting growth in galactose (permissive) 
(see PubChem Assay #AID 804). 759 active compounds 
were reassessed under both restrictive and permissive 
conditions in a 10-point 2-fold dilution series ranging 
from 0.098 - 50 μM (see PubChem Assay #AID 849).  
The top 44 DeaD lifespan-shortening compounds were 
ranked according to their ratios of restrictive 
growth/permissive growth (Supplementary Methods).  
Here we describe studies on the biological activities and 
mechanism of action of LS1 (6H-Indolo [2,3-b] 
quinoxaline: SID 4264584). 
 
LS1 is a potent lifespan shortener 
 
In yeast, nicotinamide (NAM) shortens RLS largely due 
to the compound’s activity as a feedback inhibitor of 
Sir2, though it inhibits other yeast sirtuins that affect 
lifespan and also prevents lifespan extension by caloric 
restriction by a sirtuin-independent mechanism [20-22]. 
As shown in Fig. 1A, NAM shortens DeaD lifespan at 
concentrations (IC50 = 1 mM) where it has no 
discernable effect on permissive growth. Similar to 
NAM, LS1 also exhibits dose-dependent DeaD lifespan 
shortening (DeaD IC50 = 5 μM) at concentrations where 
permissive growth is unaffected (Fig. 1B), though it is 
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~200-fold more potent than NAM. The DeaD assay 
RLS shortening activity of 1 μM LS1 was confirmed by 
standard microdissection assay (Fig. 2).  
 
LS1 acts independently from the role of Sir2 in ERC 
accumulation  
 
The RLS of yeast is normally limited by the age-
dependent accumulation of extrachromosomal rDNA 
circles (ERCs) [23].  ERC formation requires Fob1 and 
is suppressed by Sir2 activity [24, 25].  Thus fob1Δ cells 
are resistant to the lifespan shortening effects of SIR2 











































pathway, for example, by directly or indirectly 
inhibiting Sir2, we assessed the effects of LS1 in 
fob1Δ and sir2Δ strains. As shown in Fig. 3A, LS1 
effectively reduced DeaD lifespans in both fob1Δ and 
sir2Δ strains.  In contrast, NAM, which acts 
predominately by inhibiting Sir2, shows significantly 
less DeaD lifespan shortening activity in fob1Δ and 
sir2Δ strains (Fig. 3B). The modest lifespan reduction 
by NAM in fob1Δ and sir2Δ strains may be due to its’ 
sirtuin-independent RLS-shortening activities [22].  We 
conclude that LS1 shortens RLS by an ERC- and Sir2-














































in  the  presence  of  increasing  concentrations  of  nicotinamide  (NAM)  (A),  LS1  (B),  ellipticine
(ELLIP) (C) and doxorubicin (DOX) (D) under nonpermissive (●) and permissive (○) conditions.   

















































LS1 is toxic in cells lacking homologous 
recombination 
 
To gain insight into the mechanism of action of LS1 we 
performed a genome-wide chemical-genetic screen for 
deletions of nonessential genes that caused slow growth 
in the presence of LS1. This screen identified a set of 

















































for homologous recombination. Specifically, LS1 caused 
a slow growth phenotype in rad51Δ, rad52Δ, rad54Δ, 
rad57Δ, and mre11Δ cells. LS1 had no vegetative growth 
effect on yku70Δ or yku80Δ cells that are defective in 
DSB repair by nonhomologous end joining (NHEJ) (Fig 
4A). Thus HR, but not NHEJ, is necessary for resistance 
to LS1. FACS analysis revealed that LS1-treated rad52Δ 
cells tended to arrest growth at G2/M (Fig. 4B). Parental 
 
Figure  2.    LS1  shortens  replicative  lifespan  by  standard  microdissection  assay.
Microdissection in the presence and absence of 1µM LS1 was performed as described in Materials and
Methods.  LS1 treated (●) FY839 cells had an average lifespan of 16.1 generations, a 41.5% drop from
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cells treated with LS1 did not show a cell cycle 
phenotype.  The growth defect of top1Δ cells in the 
presence of LS1 was of interest, since the only class of 
DNA damaging agents that have been reported to result 




















































poisons [26]. top1Δ mutants are hypersensitive to Top2 
poisons because these cells rely on Top2 for all 
topoisomerase functions that are normally shared by 
Top1 and Top2 [9, 10, 27]. Thus the sensitivity of top1Δ 




















































Figure 4.   Synthetic genetic  interactions of LS1 with RAD52 epistasis group deletions.   A comprehensive






























The synthetic growth defect of LS1 in rad52Δ cells is 
quantified in Fig. 4C and shows that the slow growth 
phenotype of RAD52+ cells at very high LS1 
concentrations is not due to cell death (Fig. 1B).  
Interestingly, these data show that in the absence of LS1 
rad52Δ log cultures contain a steady state level of ~2% 
dead cells compared with less than 0.5% in RAD52+ 
cultures (Fig. 4C). Although a death rate of ~2% per 
generation would be undetectable by standard methods 
used to quantify growth, these levels are amplified in 
RLS studies. Adding 1%, 2%, or 3% non-age-associated 
cell death/generation reduces the mean RLS of parental 
cells by 19%, 31% and 45%, respectively (Fig. 2). 
Therefore, the observed ~30% reduction in mean RLS 
caused by 1 μM LS1 could be explained if LS1 killed 
~2% of cells/generation. In fact, LS1 had an 
insignificant effect on the numbers of dead cells in 
exponentially dividing cultures, which carry about 0.5% 
dead cells/generation, even at concentrations as high as 
50 μM (Fig. 4).  Steady state levels of age-independent 
cell death in log phase rad52Δ cultures could be 
responsible for the significant fraction of the published 
short RLS of this and other purportedly short-lived 
strains [28]. Numbers of nonviable rad52Δ cells 
increased dramatically during stationary phase (not 
shown), consistent with the report that RAD52 is 
required for full chronological lifespan [29].  We 
conclude that the shorter RLS of LS1-treated cells is not 
due to low levels of non-age-related cell death, as may 
be the case for strains such as rad52Δ.  
 
Together, these results suggest that the lack of toxicity 
of LS1 toward young cells at concentrations where it 
exhibits strong lifespan shortening activity in old cells 
could be due to an age-associated decrease in the 
capacity of older cells to sense and repair LS1-induced 
DNA damage. It follows that the lifespan shortening 
activity of LS1 could be explained by an age-dependent 
decline in DNA repair systems [2, 30]. We hypothesize 
that LS1 is selectively toxic in older cells that have 
diminished capacity to efficiently either sense or repair 
















































Figure  4.    Synthetic  genetic  interactions  of  LS1  with
RAD52 epistasis group deletions.   (C) Quantitative effect of
increasing concentrations of LS1 on cell viability in log cultures of










COR  fluorescent  imaging  system  (not  shown).  (B)  Quantitative
effect  of  LS1  concentrations  on  growth  of  TOP2  overexpressing
strain  compared  to  cells  containing  the empty  vector. Maximum
growth  rates  were  calculated  from  triplicate  growth  curves
generated  using  a  BioScreen  C  system  and  BGFit  webserver  as
described in Materials & Methods. 
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LS1 is a TOP2 poison 
 
LS1 is basically the unsubstituted scaffold of ellipticine, 
a Top2 poison [31, 32]. If LS1 were simply a weak 
Top2 poison, then other Top2 poisons dosed at subtoxic 
concentrations might also reduce RLS. Two structurally 
distinct Top2 poisons, ellipticine and doxorubicin, were 
tested using the DeaD assay for RLS shortening 
activity. Ellipticine and doxorubicin shorten apparent 
DeaD lifespan simply by virtue of their being cytotoxic 
(Fig. 1C & D).  
 
We performed a simple in vivo test for yTop2 poisoning 
by LS1.  Because yTop2 participates directly in the 
formation of cleavage complexes, cells expressing 







































numbers of cleavage complexes and are, therefore, more 
sensitive to poisons [26]. Consistent with LS1 being a 
Top2 poison, over-expression of TOP2, but not TOP1 
or TOP3, increased LS1 toxicity (Fig. 5A).  The dose-
dependent toxicity of LS1 in cells expressing native or 
many-fold higher levels of yTop2 is also consistent with 
a Top2 poisoning mechanism (Fig. 5B). Interestingly, 
even at high concentrations LS1 did not completely 
inhibit growth in cells expressing native levels of 
yTop2. This is interesting because yeast TOP2 is an 
essential gene, so strong inhibition should either be 
lethal or at least cause strong growth defects. It is 
possible that the cell’s repair and remediation pathways 
cope with a limited number of LS1-induced Top2ccs 
and, in the steady state, regenerate a sufficient pool of 
Top2 to perform essential roles. In contrast, doxorubicin 
and ellipticine completely inhibited growth of cells 
expressing native TOP2 levels (Fig. 1C & D). Higher 
concentrations LS1 had even greater inhibitory effects 
on the growth of cells overexpressing TOP2, indicating 
that presumptive remediation pathway(s) can be 
overwhelmed (Fig. 5B).  
 
Based on these in vivo results we directly tested LS1 for 
inhibition of Top2 enzyme activity. Fig. 6A shows that 
LS1 inhibited kinetoplast DNA decatenation by human 
Top2α (IC50 = 3 μM).  Unlike some Top2 poisons, 
including ellipticine and doxorubicin, LS1 did not 
detectably intercalate into DNA (Fig. 6B). This finding 
is consistent with a previous study concluding that LS1 
does not bind DNA in contrast to other quinoxaline 
analogs [33].  A lack of DNA binding or intercalation 
ability does not by itself explain the lack of toxicity of 
LS1, since etoposide, another well studied, 
nonintercalating Top2 poison is cytotoxic. 
 
Top2 poisons induce the accumulation of DSBs, either 
by promoting the formation of Top2cc adducts or by 
slowing their re-ligation, making them aberrantly long-
lived. Parenthetically, bisdioxopiperazines such as 
ICRF-193 promote non-covalent but tightly bound Top2 
which are toxic because they interfere with transcription 
and other DNA metabolic processes; however, because 
the toxicity of these molecules is not enhanced by 
mutations in the RAD52 pathway it is unlikely that 
DSBs are generated [34, 35]. In support of the 












topoisomerase  I  (Top1) DNA unwinding assay was used  to assess  the ability of LS1  to  intercalate as  indicated  in Methods. Known Top2
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LS1 promotes the in vitro formation by yTop2 of DSBs 
in plasmid DNA (Fig. 7A & B), albeit less efficiently 
than etoposide.  
 
LS1 enhances the potency of chemotherapeutic Top2 
poisons in yeast and cancer cells  
 
We hypothesized that LS1 induces the formation of 
Top2cc adducts that, in the absence of robust 
homologous recombination, cause cell death by the 
same mechanism—DNA damage—as classic Top2 
poisons.  However, unlike other Top2 poisons, LS1 is 
not toxic at concentrations where it has strong effects on 
RLS (Fig. 1B). We reasoned that LS1-Top2ccs might be 
more prone to lethal poisoning by a second more toxic 
poison. Thus LS1 could at least transiently target Top2 
to DNA, effectively increasing the target population for 
attack by lethal Top2 poisons. As a test we quantified 0, 





































and absence of 0 -100 μM LS1 in yeast cells expressing 
native or overexpressed levels of TOP2.  In cells 
expressing native levels of Top2, etoposide exhibited 
little toxicity with or without LS1 (Fig. 8A).  As 
expected from a Top2 poison, etoposide exhibited a 
strong dose-dependent toxicity in cells overexpressing 
TOP2 (Fig. 8B).  A physiologically relevant concentra-
tion of 10 μM LS1, which alone caused less than ~2-
fold cell death in TOP2 overexpressing cells, enhanced 
1 or 5 μg/ml etoposide toxicity by 10 and 8-fold, 
respectively.  We hypothesize that LS1 enhances 
etoposide toxicity by transiently stabilizing Top2ccs 
that serve as good targets for etoposide poisoning.  
 
Based on the enhancement of etoposide cytotoxicity in 
yeast, we asked if LS1 might enhance the toxicity of 
Top2 poisons to human cancer cells. Doxorubicin is a 
frontline chemotherapeutic for both solid and liquid 
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doses of doxorubicin are limited by cardiotoxicity [36, 
37]. As a test of principle, human HT1080 fibrosarcoma 
cells were incubated with or without increasing 
concentrations of doxorubicin.  As shown in Fig. 9A & 
B, LS1 alone is nontoxic to HT1080 cancer cells, but it 
enhances cell killing by doxorubicin up to fivefold.  In 
contrast, LS1 did not enhance the toxicity of 
doxorubicin to noncancerous HCA2T human primary 
foreskin fibroblasts (Fig. 9C).  LS1 also enhanced 
etoposide toxicity in HT1080 cells (data not shown).  
The fact that LS1 enhanced the toxicity of Top2 poisons 
in both yeast and human cancer cells indicates that it 
acts by poisoning Top2 in both species.  The 
stimulatory interaction between LS1 and two 
chemically distinct Top2 poisons supports our 
conclusion that the physiological target of LS1  is  Top2.   








































the potency of doxorubicin and etoposide by inhibiting  
multidrug resistance (MDR) pumps such as P-
glycoprotein. Inhibition of P-glycoprotein increases 
intracellular concentrations of a broad range of 
xenobiotics, including vinblastine, resulting in greater 
drug potencies [38]. Since LS1 did not increase the 
toxicity of vinblastine in HT1080 cells (Fig. 9A, right 
panel) we conclude that the enhancement of 
doxorubicin toxicity by LS1 is not due to direct or 
indirect inhibition of MDR pumps.  
 
Reducing Top2 activity extends RLS  
 
The above results are consistent with the hypothesis that 
LS1 enhances the potency of Top2 poisons in both yeast 
and human cancer cells by increasing the effective 











































TOP2)  increased  sensitivity  to ETOP  in  the presence of LS1. Yeast  strain YMM10  [80], which contains
gene deletions in several drug efflux pumps, was used to promote ETOP sensitivity.  
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causing activity.  This model suggests that reducing 
yTop2 activity could reduce intrinsic levels of DNA 
damage and actually extend RLS.  Investigating the 
effects of reducing yTop2 levels must take into account 
that TOP2 is an essential gene in yeast, and that both 
its’ strong over- and under-expression cause growth 
defects [39, 40].  The first approach we took was to 
quantify DeaD lifespans of novel hypomorphic top2 
point mutants that were isolated by virtue of being 
resistant to LS1 (Fig. 10A), but exhibited no growth 
defects (not shown). These point mutations mapped to 
diverse sites within the protein (Fig. S6). Cell extracts 
from a number of these strains showed several-fold 











































shown for one, top2-28 (Fig. 10C), all of these mutants 
conferred resistance to doxorubicin, ellipticine and 
etoposide. The properties of these mutants are 
consistent with previously characterized hypomorphic 
alleles that, as would be expected from general loss of 
function mutations, confer resistance to multiple Top2 
poisons [41-43].  
 
As shown in Fig. 11A, top2-28 cells, which express 
reduced yTop2 activity (Fig. 11B), exhibited a 
significantly longer DeaD lifespan when compared to 
cells expressing wild type TOP2 (Fig. 11A). To validate 
and extend these DeaD assay results, we performed 















































and HCA2T cells were seeded at  low density.   After 24 hours, cells were treated with DMSO  (vehicle control) or DMSO
containing DOX  at  the  indicated  concentrations without  or with  10µM  LS1. DMSO  and DOX  data were  based  on  the
average of 6 biological replicates.  Vinblastine data was based on three biological replicates.  Average values and standard
deviation of the mean are plotted where available. P‐values determined by student t‐test are shown for DOX.  
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expressing TOP2-DAmP gene [44]. This strain 
expresses native TOP2 at approximately 30% wild-type 
levels (Fig. 11C), but exhibited no apparent growth 
defect (not shown). Since the haploid strain containing 
the TOP2-DAmP allele was generated from the 
heterodiploid and compared to the haploid strain 
containing the TOP2 wild-type allele, the strains were 
isogenic except at the TOP2 locus.  As shown in 
Fig.11D, constitutively reducing yTop2 levels extended 
both mean and maximum RLS.  
 
The budding index of the terminally senescent mothers 
from the microdissection assays revealed that TOP2-










































ded (G1) cells (Fig. 11E).  Low budding indexes of 
senescent mother cell populations indicate robust 
growth control at G1/S checkpoints, and correlate with 
longer microdissection [28] and microfluidics-based 
RLS assays [45-47]. Therefore, wild type levels of 
yTop2, which are presumably tuned to optimize 
proliferative growth, are deleterious in aging cells—a 




We describe novel biological properties of a drug-like 
molecule identified in a high throughput DeaD assay 
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originally described as the unsubstituted scaffold used 
in the development of less cytotoxic analogues of 
ellipticine [32]. In vivo and in vitro evidence show that 
LS1, like ellipticine, is a Top2 poison, albeit weaker and 
significantly less cytotoxic. LS1 exhibits none of the 
cytotoxicity to cancer (or normal) cells that ellipticine 
and other chemotherapeutic Top2 poisons show.  LS1 
inhibits the in vitro decatenation activity of human 
TOP2-α, and induces yTop2 to generate stable DSBs 
(Top2ccs) in plasmid DNA. Like known Top2 poisons, 
LS1 is toxic to cells overexpressing TOP2 and to cells 
deleted for RAD52 epistasis group genes.  The latter 
synthetic interaction indicates that homologous 
recombination is needed to repair Top2ccs formed in 
the presence of LS1, and suggested the hypothesis that 
LS1 is toxic to aging cells, which, like young 
rad52Δ cells, may exhibit a diminished capacity to 






































A key finding in our study is that yeast cells live longer 
when expressing reduced levels of yTop2.  We propose 
that the Top2 poison activity of LS1 accelerates aging 
by presenting higher than normal Top2cc levels to aging 
cells with declining genome maintenance systems [14-
17].  It follows that decreasing yTop2 levels would 
extend RLS by reducing DNA damage to levels below 
that which cause normal rates of senescence. The idea 
that Top2 is a natural source of DNA damage is not 
new. Top2-mediated DNA damage has previously been 
implicated in physiologically normal processes [11]. In 
mammals, TOP2β-induced DSBs are necessary for the 
regulated transcription of neuronal early-response genes 
[50] and for TOP2β mediated androgen-induced DNA 
rearrangements in prostate cancer [51]. C. elegans top-2 
is also responsible for a striking increase in DNA 
damage during zygotic genome activation [52]. The 






































Figure  11.    Reduced  Top2  activity  extends  replicative  lifespan.  (A)  DeaD  cells  expressing  top2‐28
displayed  a  roughly  two‐fold  increase  in  lifespan  both  in  the  absence  or  presence  of  LS1  compared  to  cells
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entry of larval primordial germ cells into the cell cycle 
triggers widespread DNA damage and activates DNA 
damage checkpoints that slow entry into mitosis.  
Remarkably, reducing top-2 expression both reduced 
levels of DSBs in germ line cells and accelerated their 
entry into mitosis, presumably by precluding the need 
for the DNA damage checkpoint. This phenomenon 
provides a precedent for our hypothesis that a reduction 
in yTop2 expression decreases DNA damage in old 
cells and extends RLS. As suggested by an apparent 
loss of checkpoint control and increased rates of loss of 
heterozygosity (LOH) in the daughters of old mothers 
[53, 54], old yeast cells proceed through mitosis before 
damaged chromosomes can be repaired.  
 
Proving that a molecule selectively shortens RLS is 
challenging because even low levels of toxicity—either 
cytotoxic or cytostatic—will reduce apparent RLS by 
arresting cell division irrespective of age. An effective 
lifespan shortening agent should have little effect on the 
physiology of log-phase cells, ~87% of which are 3 
generations or younger, even when the target is an 
essential housekeeping factor like yTop2.  As is the case 
with many drugs that target physiologically important 
targets, the dose-dependence of lifespan shortening 
compounds is critical to limiting the toxic side effects 
associated with targeting essential longevity factors.  
LS-1 does become toxic at very high doses, possibly 
due to over-inhibition of yTop2 or off-target effects, or 
a combination of both. The initial DeaD screen included 
both permissive and nonpermissive assays that provided 
a filter to exclude molecules such as doxorubicin and 
etoposide that are toxic under permissive conditions 
(Fig. 1C & D). In contrast, LS1 and NAM reduce DeaD 
lifespan at concentrations that have no apparent effects 
on permissive growth. Besides having no effect on 
growth rate, LS1 has no discernable effects on either the 
cell cycle or viability. The viability criterion is 
important because even low levels of nonage-associated 
cell death cause significant  decreases in apparent RLS 
using the microdissection assay.  For example, 
rad52Δ cells, which had previously been argued to be 
short-lived [28], died in log phase at a rate of 
~2%/generation. A 2% cell death rate has a negligible 
impact on proliferative growth, but reduces mean RLS 
by ~30%.  LS1 has no detectable effect on cell viability 
even at concentrations 70-fold higher than were 
sufficient to reduce RLS by ~30%. We conclude that 
LS1 is a bona fide lifespan-shortening probe that is 
~200-fold more potent than NAM.   
 
An age-associated decline in genome maintenance 
creates a situation where otherwise manageable levels 
of DNA damage become toxic. We propose that LS1 is 
selectively toxic to older cells that have lost the capacity 
to mitigate yTop2-induced DNA damage, either by 
failing to properly repair Top2ccs or by failing to 
efficiently activate the DNA damage checkpoint and 
stalling the cell cycle until the damage can be repaired. 
As described above, older diploid yeast mother cells 
switch to a state of high genome instability that 
continues to produce high levels of LOH in daughters 
until the mothers die [53, 54].  LOH in the daughters of 
older mother cells is primarily due to damage-prone 
breakage induced repair (BIR) of DSBs. Moreover, 
unlike young cells that delay the cell cycle in order to 
repair DSBs, old mothers that produce daughters with 
LOH do not exhibit cell cycle delay or arrest, consistent 
with a loss of the DNA damage checkpoint [53, 54].  
These studies argue that LOH in aging yeast arises not 
from an increase in the rate of DNA damage, but rather 
in the loss of genome maintenance systems needed to 
repair damage. Increased genomic instability in the 
form of LOH also rises dramatically during chronolo-
gical aging.  Interestingly, although chronological and 
replicative lifespans of natural isolates are not 
correlated [4], variability among natural isolates in the 
lag between the rise in LOH and loss of viability during 
chronological aging does correlate with the RLS of 
natural isolates, and argues that the capacity to resist 
genome instability contributes to natural variation in 
RLS [55-57].  LS1 does not affect chronological 
lifespan (M. Weinberger and W. Burhans, personal 
communication), consistent with the notion that Top2 
poisoning by LS1 is selectively toxic to replicating 
cells, presumably by interfering with genome 
maintenance during and following DNA replication.  
 
Are our results consistent with what others have 
observed in aging yeast?  Whereas Hu et al. [58] 
observed numerous genome rearrangements in older 
mother cells, Kaya et al. [55] sequenced the genomes of 
colonies produced by daughters of individual old 
mother cells and found only low numbers of mutations, 
effectively ruling out the accumulation of mutations in 
the mothers as the cause of senescence. Our results are 
consistent with both of these studies. A single 
unrepaired DSB in a mother cell that has lost the 
capacity to either sense or repair the damage can be 
lethal.  This type of damage would not manifest itself as 
DNA damage in the genomes of daughter cells. 
Accordingly, in the case of yTop2-mediated DNA 
damage, it is not the accumulation of mutations that 
leads to senescence, but rather as few as a single 
catastrophic DSB—those not transmitted to daughters 
because the mothers die—that lead to age-associated 
cell death.   
 
Our observation using microdissection RLS assays that 
terminal mothers under-expressing TOP2 exhibit a 
higher frequency of arrest as unbudded G1/S cells 
compared to normal cells is consistent with improved 
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checkpoint function.  Consistent with the idea that 
normal levels of yTop2 cause RLS-limiting DNA 
damage and loss of growth control, Delaney et al. [28] 
reported that mutations that cause defects in genome 
stability genes tend to shorten RLS and increase the 
proportion of mothers that senesce as budded cells.  
Moreover, there is a strong statistical correlation 
between RLS and the budding index of terminal 
mothers, the latter of which can vary between ~25-70%.  
Since not all mothers senesce as budded cells, it is 
unlikely that DNA damage and loss of growth control is 
the only mechanism that limits RLS in yeast. Thus we 
conclude only that yTop2-induced DNA damage 
contributes to aging.  
 
Beyond studies in yeast, genome instability or defects in 
genome maintenance are strongly correlated with aging 
[2, 12, 59, 60].  Strong evidence in support of the DNA 
damage theory of aging includes progeroid syndromes 
in humans and rodents that are associated with 
mutations that affect genome maintenance (reviewed in 
[2]).  Additional evidence comes from studies showing 
that DNA repair systems decline in older animals [61-
63].  The specific role of DSBs in aging is supported by 
the appearance of age-associated phenotypes in mouse 
liver following the selective induction of DSBs in that 
tissue [64]. Age-associated defects in growth signaling, 
resulting in inappropriate entry into S-phase before 
DNA damage can be sensed and repaired, or before 
adequate stores of nucleotides are available, can lead to 
catastrophic events such as replication fork collapse and 
irreparable arrest at G2/M [65].  But these observations 
do not address whether DNA damage is cause or 
consequence of aging. What has been lacking in support 
of the DNA damage theory of aging are cases, such as 
we show in the case of yTop2, where lifespan is 
extended by reductions in DNA damage or by increases 
in repair systems or DNA damage checkpoints.  Some 
evidence, such as the extended lifespan of male mice 
that overexpress SIRT6 [66], which is known to 
increase expression of DNA repair systems [67], are 
confounded by the pleiotropic roles of SIRT6 [68]. 
Similarly, RLS extension in yeast by overexpressing 
histones, which normally become depleted by about 
50% in aging yeast, results in a global increase in 
transcription, suggests that this form of decline in 
genome maintenance plays a role in aging and, 
importantly, can be mitigated [69].  
 
The antagonist pleiotropy (AP) theory of aging posits 
that the normal activities of some genes are beneficial 
during development and reproduction, but, for whatever 
reason(s), promote senescence later in life [48, 49].  The 
mutation accumulation (MA) theory posits that aging 
results from the accumulation of mutations that are 
selectively deleterious only late in life [48, 49]. Both 
theories depend on the assumption that AP genes or MA 
alleles escape natural selection because their phenotypes 
manifest post-reproductively.  Our results indicate that 
yeast TOP2 is an AP gene. If we assume that DNA 
damage by yTop2 occurs at approximately constant 
rates throughout yeast lifespan, then the AP properties 
of TOP2 require an age-associated decline in genome 
maintenance similar to that which produces LOH in the 
daughters of old mother cells. This scenario is 
inconsistent with the MA theory of aging because most 
of these deleterious mutations would be deleterious 
whether they occurred early or late in life.  In any case, 
Kaya et al. [55] did not find a significant accumulation 
of age-associated mutations.  Thus our results with 
yTop2 support the AP theory of aging. yTop2 activity is 
required for proliferation in young cells, but it becomes 
toxic late in life.  Thus yTop2 is indirectly anta-
gonistically pleiotropic as its effect on longevity 
depends on an age-associated decline in genome 
maintenance. If correct, the AP effects of TOP2 could 
be mitigated late in life, either by moderately reducing 
TOP2 expression to levels that do not affect 
proliferation, which we have shown to be possible, or 
by enhancing repair or damage sensing and checkpoint 
systems later in life. In addition to yTop2, other DNA 
cleaving or modifying enzymes that have potential to 
cause DNA damage with AP properties such as 
Topoisomerase 1 [70, 71] may contribute to aging and 
age-associated diseases.   
 
MATERIALS AND METHODS 
 
Strains and LS1 chemical-genetic interactions 
 
Negative chemical-genetic interactions with LS1 were 
initially determined by replica plating spots of similarly 
diluted mid-log cultures of the Yeast deletion collection 
library (GE Life Sciences; [72, 73]) on SCD and SCGal 
media lacking or containing 20µM LS1.  Any patch 
showing less growth was confirmed more thoroughly by 
replica plating a series of spot dilutions of log-phase 
(OD600=1.0) cultures on media containing either 
DMSO (0.1%) in the absence or presence of various 
concentrations of LS1.  To test if LS1 is a topoiso-
merase poison, high copy number plasmids from the 
Yeast Tiling Collection (Thermo Scientific) containing 
TOP1, TOP2, and TOP3 genes were isolated and 
transformed into the parental yeast strain BY4741 using 
Li-acetate/PEG with LEU2 as the selectable marker. 
[74].  
 
Low to moderate throughput liquid culture DeaD 
assays 
 
Strains carrying the three DeaD assay loci 
(GAL1:CDC6, HO:CDC6, and the partial deletion of 
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the ASH1 promoter) are grown two days on YP/2% 
galactose agar plates. A single colony of each strain is 
suspended in water and used to inoculate small (1-3 
mL) cultures in SCRafGal (SC/ 1.9% raffinose/ 0.1% 
galactose, USBiologicals, Swampscott MA) for 
overnight growth to early log phase (to ensure early log 
phase by the next day, we typically do parallel 
inoculations at calculated optical densities (600nm) of 
0.0001, 0.00003, and 0.00001). After overnight growth, 
one culture of each strain is used to inoculate SC/2% 
glucose and SCRaffGal at a calculated OD600 of 
0.0001. Using a BioScreen C plate reader (Growth 
Curves USA, Piscataway NJ), cultures are grown at 
30°C for 3 days, with an optical density (600 nm) 
reading taken every 20 minutes. 
  
To calculate “DeaD lifespan,” we use the restrictive (i.e. 
SC/2% glucose) optical density reading at 60 hours, 
normalized to the estimated number of doublings that 
have occurred. To estimate the number of doublings, we 
use the actual number of doublings in permissive (i.e. 
SCRaffGal) medium in the first 24 hours, plus 36 times 
the calculated number of doublings per hour derived 
from the culture growth from hour 18 to hour 24. This 
assumes that the restrictive growth medium does not 
become limiting during the course of the assay, an 
assumption that is supported by restrictive optical 
density readings that are typically in the range of 0.1 to 
0.3 at 60 hours.  Growth rates expressed as the 
reciprocal of the doubling time (1/DT). 
 
TOP2 mutagenesis and isolation of LS1-resistant 
yeast 
 
A plasmid (YCpDED1-yTOP2) containing yeast TOP2 
gene under the control of DED1 promoter and strain 
JN394top2-4 (MATa ura3-52 leu2 trp1 his7 ade1-2 
ISE2 rad52::LEU2 top2-4) containing a temperature 
sensitive allele of TOP2 in a rad52∆ background were 
employed [26].  YCpDED1-yTop2 plasmid was 
maintained by URA selection. Hydroxylamine 
mutagenesis of the plasmid was performed as 
previously described [41, 75].   Mutations in the 
plasmid copy of the yeast TOP2 gene that retained 
function yet were resistant to LS1 were obtained by 
selection at the restrictive temperature (35°C) where the 
chromosomal TOP2 ts2-4 allele is non-functional by 
including 20µM LS1 in the growth media.  The 
resistance of individual strains carrying TOP2 mutations 
was checked by plating spot-dilutions on SCD-URA 
plates containing either DMSO carrier or DMSO with 
20µM LS1 added.  To rule out potential mutations in 
the strains as a cause of LS1 resistance, strains were 
cured for the pDED1-yTOP2 mutagenized plasmid by 
treatment with 5-floroorotic acid (5-FOA), and 
subsequently tested for LS1 resistance.  Reciprocally, 
pDED1-yTOP2 mutagenized plasmids were also 
rescued from strains showing resistance to LS1, 
transformed into naïve JN394t2-4 and re-tested for 
resistance to LS1.  Growth in liquid media (SCD-URA) 
containing various concentrations of LS1 was measured 
in a Bioscreen C instrument (Growth Curves USA; 
Piscataway, NJ).   Relative growth rates (∆O.D.600/h) 
of JN394t2-4 containing pDED1-yTOP2 (wild-type or 
mutant derivatives) were measured for up to 60h after 
an initial inoculum of .005 OD600 units.  Growth data 
were fit to obtain maximum growth rates using the 
BGFit webserver [76].   
 
Inhibition of human Topoisomerase 2-alpha (hTop2-
α) 
 
LS1 inhibition of hTop2-α was determined by 
measuring the effect of LS1 on the ability of hTop2-α to 
decatenate kinetoplastid DNA from Crithidia 
fasciculata.  Human Top2-α was added to 0.2µg of 
kDNA (both were purchased from Topogen, Inc; Buena 
Vista, CO) in the presence of 1% DMSO (vehicle 
control) without or with increasing concentrations of 
LS1 as indicated.  Samples were incubated at 37°C for 
15min, and then reactions were terminated by the 
addition of an SDS buffer.  Samples were resolved by 
1% agarose 1xTAE gel and stained with ethidium 
bromide.  Decatenated versus intact kDNA species were 
quantified by densitometry using GelQuant.NET1.8.2 
software.  Final % products were plotted using 
KaleidaGraph software. 
 
Tissue culture cell growth 
 
All cell lines were grown in monolayer at 37°C in 3% 
O2, 5% CO2 and 97% relative humidity in HERA Cell 
240 incubators on treated polystyrene cell culture plates 
(Corning). Immortalized human fibroblast cells 
(HCA2T) were maintained in MEM (ATCC) 
supplemented with 15% FBS (Gibco) and 1x Pen/Strep 
(Gibco). Human fibrosarcoma cells (HT1080) were 
maintained in DMEM (Gibco) supplemented with 10% 
FBS (Gibco), 1x Pen/Strep (Gibco) and 1x nonessential 
amino acids (Gibco). 
 
Tissue culture cell survival 
 
HT1080 and HCA2T cells were split to a density of 1 × 
105 cells per well of a six well plate 24 hours prior to 
treatment with the indicated concentration of DMSO 
(Sigma), Doxorubicin (Sigma), Vinblastine (Sigma) and 
LS1. All drugs were concurrently applied to the cells. 
Cell survival was measured 48 hours after treatment by 
counting the adherent cells in each group using a Z2 
particle counter (Beckman Coulter). The ratio of 
adherent drug-treated cells to adherent cells treated with 
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DMSO represents the raw survival. Experiments using 
doxorubicin were repeated six times; experiments using 




Anti-yTop2 polyclonal antibodies were purchased from 
Topogen (Buena Vista, CO).  For the TOP2 tiling 
experiments, protein extracts were prepared using the 
rapid boiling method [77].  When cells were grown in 
minimal media, protein extracts were prepared using the 
glass bead method [78].  Secondary antibodies 
conjugated to infrared dyes (LI-COR; Lincoln NE) were 
employed with an infrared gel scanner (LI-COR; 
Lincoln NE) for quantitation of the western blots.   
 
DNA intercalation assay 
 
DNA Topoisomerase I (Top1) –based assay was used to 
assess the ability of LS-1 to intercalate.  This approach 
relies upon linking number changes in supercoiled 
plasmid DNA induced by the intercalating molecule 
[79] which can be compared to DNA that was not 
treated.  After treatment with the putative intercalator, 
linking number changes can be inferred after relaxation 
with DNA Top1.  If intercalation occurred, upon 
removal of Top1, the final linking number (or state of 
supercoiling) will be distinct compared to DNA that 
was not treated (control).  Molecules that fail to 
intercalate appear similar to control samples.  DNA was 
incubated with DMSO alone or DMSO containing the 
indicated amount of doxorubicin, etoposide, or LS-1 for 
15min at 25°C, followed by an additional 1h with added 
Top1.  Next, DNA was extracted with phenol and 
chloroform and precipitated with ethanol.  Samples 
were resolved by electrophoresis through 1% agarose 
1xTAE gel and species were quantitated by 
densitometry with GelQuant.NET1.8.2 software.   
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SUPPLEMENTARY MATERIAL 
 
Construction and characterization of an improved 
DeaD strain 
 
K6001 is a W303-derived strain that was originally 
constructed for use in the study of mother cell-specific 
mating type switching [72, 73]. K6001 encodes two 
integrated copies of the essential gene CDC6, 
independently regulated by the repressible GAL1 
promoter and the mother cell-specific HO promoter, 
respectively (GAL1:Ub:CDC6 and HO:CDC6). 
Previously, we exploited this strain as an alternative to 
the standard microdissection method of quantifying 
replicative lifespan (RLS), which is labor intensive and 
slow [74]. When K6001 cells are grown permissively in 
galactose-containing media (raffinose/galactose), 
GAL1:CDC6 is expressed both in mother and daughter 
cells and the culture grows exponentially. When 
expression of the GAL1:CDC6 gene is repressed by 
glucose, only the mother-cell-specific expression of 
HO:CDC6 remains to support growth. Since HO 
expression is largely restricted to mother cells, 
daughters generally do not divide and growth of the 
culture is limited by the RLS of the initial cohort of 
mother cells.  Since the success of this strategy depends 
on the conditional Death of Daughter cells, we call it 
the “DeaD” assay.  Although promising, K6001 as a 
DeaD strain exhibited significant limitations. Its mother 
cells cease division on glucose after an average of only 
3-4 divisions [74]. K6001 also has a short average 
lifespan under permissive conditions, presumably due to 
its W303 background (17 generations for K6001 [74], 
similar to 20.8 generations for W303R [18]). Early tests 
of the assay showed a reduction of DeaD lifespan by 
deletion of SIR2 [74] but these tests ignored the fact that 
the HO:CDC6 fusion is haploid-specific [75]. Deletion 
of SIR2 prevents silencing of the mating type 
information at HML and HMR and thus renders cells 
pseudo-diploid [76, 77]. After a switch to glucose, sir2Δ 
mutants will thus be unable to express either copy of 
CDC6 (see below for mechanism of HO gene 
expression) and will die rapidly, as was observed [74]. 
When the opposite mating type information was deleted 
from this strain, allowing HO:CDC6 expression to 
sustain mother cells in glucose, no difference in DeaD 
lifespan was observed between SIR2 and sir2Δ cells 
(data not shown). Combined with the other limitations, 
this finding indicated that the strategy exemplified by 
K6001 would have to be modified before it could be 
used as a platform for studying replicative lifespan. 
  
We began by switching the parental background from 
W303 to the longer-lived S288C background [78]. For 
galactose-specific CDC6 expression, we chose the 
strategy employed in K6001: a ubiquitin:CDC6 fusion 
driven by the GAL1 promoter. The N-terminal ubiquitin 
fusion allows modification of the amino terminus of 
Cdc6 to reduce protein stability and tighten control over 
Cdc6 activity. The ubiquitin moiety is co-translationally 
removed by ubiquitin processing proteases, and the 
amino acid serving as the new amino terminus of Cdc6 
determines its half-life according to the N-end rule [79]. 
  
We cloned the GAL:Ub:CDC6 fusion from K6001 to a 
plasmid vector. DNA sequencing revealed a tyrosine 
codon at the beginning of CDC6, rather than the 
expected arginine [73]. Multiple independent clones 
from two separately obtained K6001 isolates gave the 
same result. According to the N-end rule, tyrosine is 
less destabilizing than arginine [79]. Rapid turnover of 
GAL1-expressed Ub-Cdc6 is required for efficient death 
of daughters after a shift to glucose.  Arginine, which is 
maximally destabilizing [79], is thus the desired N-
terminal residue. All of the clones also carried a 
conservative mutation in the ubiquitin moiety: arginine 
74 to lysine. We used PCR mutagenesis to correct this 
mutation and to change the N-terminal residue of Cdc6 
to either arginine or methionine. We then integrated 
these alleles, and the original K6001 allele, in place of 
the endogenous CDC6 in the S288C-derived strain 
Y7092 [80]. Since the GAL:Ub:CDC6 allele is the only 
source of CDC6 in these strains, all cells arrest when 
transferred to glucose, and the efficiency of this arrest is 
a function of the stability of Cdc6. Cells expressing 
arginine at the N-terminus of Cdc6 achieved the most 
efficient growth arrest. (Fig. S1A). This allele was 
incorporated into all subsequent DeaD strains.   
  
The HO:CDC6 allele in K6001 is an imprecise fusion 
of the open reading frame of CDC6 to the HO promoter: 
the fusion leaves in place more than 90bp of the CDC6 
5’ untranslated region, and all of the 3’ CDC6 
untranslated sequences. This construction excludes the 
3’ UTR of HO, which appears to play a role in mother-
cell-specificity of HO expression [81]. For our new 
DeaD strain, we therefore created a precise replacement 
of the HO open reading frame with CDC6, leaving the 
large HO promoter and the HO 3’ untranslated region in 
place. This HO:CDC6:HO fusion was integrated into a 
strain already carrying GAL1:UbR:CDC6 to create 
DeaD strain BB573. BB573 mother cells have improved 
survival on glucose compared to K6001 mother cells: 
mean RLS increased from 3.4 to 8.3 generations 
(p=5.94 x 10-13, Fig. S1B).  However, 8.3 generations is 
still much shorter than the 26-28 generation mean 
lifespan of normal SC288c-derived cells [78].   
 
To further improve mother cell survival in glucose, we 
sought to increase mother cell expression of HO:CDC6. 
Insight into expression of this fusion can be gained from 
studies of normal HO. In cells that express the wild-type 
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HO endonuclease, mother cells switch mating type at a 
rate of ~70% [82]. Inhibition of switching in the 
remaining ~30% of mothers is dependent on the 
transcriptional repressor Ash1, since deletion of ASH1 
increases mother cell switching to 95-100% [72, 82]. 
These results indicate that Ash1 is normally 
incompletely excluded from mother cells.  Ideally, Ash1 
would be completely partitioned into the incipient 
daughter cell (the bud), leaving none in the mother cell 
to repress HO expression.  
  
ASH1 is expressed at the end of mitosis, when the 
transcription factors Swi5 and Ace2 enter the nucleus 
and promote ASH1 expression by binding to four 
putative Swi5/Ace2 binding sites (predicted by the 
nucleotide sequence kGCTGr, where “K” is G or T and 
“R” is A or G, [83] in the ASH1 promoter. ASH1 
expression is dramatically decreased in swi5 ace2 
double mutants [72, 84].  We deleted the Swi5/Ace2 
binding sites, either in toto or in pairwise combinations, 
in BB573 and assessed the effect on mother and 
daughter cell survival on glucose by pedigree analysis 
(Fig. S2). Deletion of the 1st two Swi5p binding sites 
(ASH1-Δ12) caused too drastic a drop in Ash1: daughter 
cell survival dramatically increased (represented by tall 
bars in Fig. S2 panel B), compare with parental strain 
BB573, Fig S2 panel A). This effect was caused to a 
lesser extent by deletion of the middle two sites (ASH1-
Δ23, Fig. S2 panel C) or of all four binding sites (ASH1-
Δ14, Fig S2 panel D). In contrast, deletion of the 3rd and 
4th Swi5p binding sites produced a strain with enhanced 
mother cell survival without increased daughter cell 
“escape” (Fig S2 panel E). This strain, ASH1-Δ34, was 
renamed BB579 and it and its derivatives were used in 
all subsequent work. BB579 has a mean survival of 11.3 
generations on glucose (longer than its parental strain, 
BB573, p=1.77 x 10-7)   corresponding roughly to a 
model combining Gompertzian senescence with a 
stochastic death rate of 7.5% (Fig. S3 panel A). 
  
Yeast cells become sterile near the end of their lifespan 
due to de-repression of the silent HM mating type loci 
and the resulting pseudo diploidy [85]. De-repression of 
the HM loci in a DeaD strain will result in failure to 
express haploid-specific HO:CDC6, as discussed above, 
and which might cause premature death in aging cells 
and an artificially short lifespan. To investigate the 
potential benefit of preventing pseudo diploidy by 
deleting one of the two mating type loci, HMR, we 
deleted HMR in SIR2 and sir2Δ BB579 cells. We 
performed microdissection (Fig. S3 panels A and B) 
and DeaD lifespan assays (Fig. S3 panel C) of parental 
BB579 (HMR), hmrΔ, sir2Δ and hmrΔ sirΔ strains. 
Deletion of SIR2 alone produced an extremely short 
apparent RLS, presumably due to repression of HO 
expression resulting from pseudo diploidy, and deletion 
of HMR and SIR2 together gave an intermediate 
phenotype (Fig. S3 panels A and C) in both the 
microdissection and DeaD lifespan assays. None of 
these deletions had significant effects on permissive 
growth in galactose, although the hmrΔ sir2Δ strain 
exhibited a minor growth defect (Fig. S3 panel D).  By 
microdissection RLS assay, deletion of HMR slightly 
extended RLS: mean RLS increased from 11.3 to 12.1 
generations (p=1.5 x 10-2), and maximum increased 
from 32 to 45 (Fig. S3 panel B). Deletion of SIR2 in 
hmrΔ BB579 cells shortened RLS to a mean of 8.6 
generations (p=1.45 x 10-4), with a maximum of 33 
generations (Fig. S3 panel A).    
 
The above results demonstrate that SIR2 strains have 
longer DeaD assay lifespans than sir2Δ strains in the 
improved BB579 background.  To test this relationship 
further, and to determine whether the DeaD assay is 
sensitive not only to lifespan shortening but also to 
lifespan extension, we asked whether we could detect a 
range of effects on RLS by altering the expression level 
of SIR2 with a series of promoter fusions. Replicative 
lifespan varies with SIR2 expression level in yeast, 
since deletion of SIR2 shortens lifespan and an extra 
copy of SIR2 extends it [18]. There is likely to be an 
upper limit to lifespan extension by up-regulation of 
SIR2, however, since SIR2 overexpression from the 
GAL1 promoter causes toxicity and elevated rates of 
chromosome loss [86]. For our test, we used PCR-based 
integration to replace the endogenous SIR2 promoter 
with the CYC, ADH, TEF, or GPD promoter [87] in an 
HMR-deleted BB579 derivative. DeaD assay lifespan of 
the resulting strains paralleled the predicted promoter 
strength (CYC<ADH<TEF<GPD, [87]), with strains 
carrying the strongest two promoters showing extension 
of DeaD assay lifespan (Fig. S4 panel C).  
  
As expected if strong overexpression of SIR2 is toxic, 
the GPDpr:SIR2 fusion, which we expect to be more 
strongly expressed than the TEFpr:SIR2 fusion [87], 
confers no additional advantage for lifespan (Fig. S4 
panel C). None of these deletions had significant affects 
on permissive growth in galactose, although the hmrΔ 
sir2Δ strain exhibited a minor growth defect (Fig. S3 
panel B).   
  
In a parallel set of experiments, we replaced the 
endogenous SIR2 promoter with the same promoter 
series in a wild-type S288C strain and measured 
replicative lifespan using the standard microdissection 
assay. The results (Fig.4S Panel D) are a striking 
parallel to the DeaD assay findings. The TEF promoter 
extended mean lifespan by a robust 45%, while the 
stronger GPD promoter showed a lesser extension of 
22%.  We conclude that improvements to K6001 
engineered into BB579 allow recapitulation of key 
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features of yeast aging using high throughput capable 






























































































Figure S1. Characterization of  improved DeaD strain BB573.   (A) Arrest of GAL:Ub:CDC6 strains  in
glucose  is dependent on the N‐terminal residue of Cdc6p. Cells were transferred to glucose at time 0 and
growth arrest was monitored by measuring  the culture OD600. The  letter  indicates  the N‐terminal Cdc6p
residue: M: methionine,  Y:  tyrosine,  or  R:  arginine.    (B)  BB573 mother  cells  have  improved  survival  on
glucose compared to K6001 mother cells: mean RLS increased from 3.4 to 8.3 generations (p=5.94 x 10‐13). 






































































































































































Mean  and maximum  replicative  lifespans  from  (A).  (C) Representative  restrictive  liquid  cultures of  the  same  four  strains.  (D)
Parallel permissive liquid cultures. (E) Relative DeaD assay lifespans of the four strains, using data from (C) and (D) together with
two more independent experiments. Error bars are +/‐ one standard error of the mean of the three experiments. 






















































































Figure  S5. DeaD  assay  reports  replicative  lifespan  for
several  strains  that  show  reduced  lifespan  in  the
traditional  microdissection  assay.    Yeast  strains  were
obtained  from  the  gene  deletion  collection.    Replicative
lifespan  (%)  for  both microdissection  and  DeaD  assay  were
determined as described in Methods. 
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